Cargando…

Targeting mitochondrial dysfunction in amyotrophic lateral sclerosis: a systematic review and meta-analysis

Interventions targeting mitochondrial dysfunction have the potential to extend survival in preclinical models of amyotrophic lateral sclerosis. The aim of this systematic review was to assess the efficacy of targeting mitochondria as a potential therapeutic target in amyotrophic lateral sclerosis. P...

Descripción completa

Detalles Bibliográficos
Autores principales: Mehta, Arpan R, Walters, Rachel, Waldron, Fergal M, Pal, Suvankar, Selvaraj, Bhuvaneish T, Macleod, Malcolm R, Hardingham, Giles E, Chandran, Siddharthan, Gregory, Jenna M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7056361/
https://www.ncbi.nlm.nih.gov/pubmed/32133457
http://dx.doi.org/10.1093/braincomms/fcz009
_version_ 1783503474810421248
author Mehta, Arpan R
Walters, Rachel
Waldron, Fergal M
Pal, Suvankar
Selvaraj, Bhuvaneish T
Macleod, Malcolm R
Hardingham, Giles E
Chandran, Siddharthan
Gregory, Jenna M
author_facet Mehta, Arpan R
Walters, Rachel
Waldron, Fergal M
Pal, Suvankar
Selvaraj, Bhuvaneish T
Macleod, Malcolm R
Hardingham, Giles E
Chandran, Siddharthan
Gregory, Jenna M
author_sort Mehta, Arpan R
collection PubMed
description Interventions targeting mitochondrial dysfunction have the potential to extend survival in preclinical models of amyotrophic lateral sclerosis. The aim of this systematic review was to assess the efficacy of targeting mitochondria as a potential therapeutic target in amyotrophic lateral sclerosis. Preclinical studies written in the English language were identified with no restrictions on publication date from PubMed, Medline and EMBASE databases. All studies adopting interventions targeting mitochondria to treat amyotrophic lateral sclerosis in genetic or drug-induced organism models were considered for inclusion. A total of 76 studies were included in the analysis. Survival data were extracted, and the meta-analysis was completed in RevMan 5 software. We show that targeting mitochondrial dysfunction in amyotrophic lateral sclerosis results in a statistically significant improvement in survival (Z = 5.31; P < 0.00001). The timing of administration of the intervention appears to affect the improvement in survival, with the greatest benefit occurring for interventions given prior to disease onset. Interventions at other time points were not significant, although this is likely to be secondary to a lack of publications examining these timepoints. The quality score had no impact on efficacy, and publication bias revealed an overestimation of the effect size, owing to one outlier study; excluding this led to the recalculated effect size changing from 5.31 to 3.31 (P < 0.00001). The extant preclinical literature indicates that targeting mitochondrial dysfunction may prolong survival in amyotrophic lateral sclerosis, particularly if the intervention is administered early. A limitation of current research is a significant bias towards models based on superoxide dismutase 1, with uncertainty about generalisability to amyotrophic lateral sclerosis with an underlying TAR DNA binding protein 43 proteinopathy. However, further mechanistic research is clearly warranted in this field.
format Online
Article
Text
id pubmed-7056361
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-70563612020-03-04 Targeting mitochondrial dysfunction in amyotrophic lateral sclerosis: a systematic review and meta-analysis Mehta, Arpan R Walters, Rachel Waldron, Fergal M Pal, Suvankar Selvaraj, Bhuvaneish T Macleod, Malcolm R Hardingham, Giles E Chandran, Siddharthan Gregory, Jenna M Brain Commun Original Article Interventions targeting mitochondrial dysfunction have the potential to extend survival in preclinical models of amyotrophic lateral sclerosis. The aim of this systematic review was to assess the efficacy of targeting mitochondria as a potential therapeutic target in amyotrophic lateral sclerosis. Preclinical studies written in the English language were identified with no restrictions on publication date from PubMed, Medline and EMBASE databases. All studies adopting interventions targeting mitochondria to treat amyotrophic lateral sclerosis in genetic or drug-induced organism models were considered for inclusion. A total of 76 studies were included in the analysis. Survival data were extracted, and the meta-analysis was completed in RevMan 5 software. We show that targeting mitochondrial dysfunction in amyotrophic lateral sclerosis results in a statistically significant improvement in survival (Z = 5.31; P < 0.00001). The timing of administration of the intervention appears to affect the improvement in survival, with the greatest benefit occurring for interventions given prior to disease onset. Interventions at other time points were not significant, although this is likely to be secondary to a lack of publications examining these timepoints. The quality score had no impact on efficacy, and publication bias revealed an overestimation of the effect size, owing to one outlier study; excluding this led to the recalculated effect size changing from 5.31 to 3.31 (P < 0.00001). The extant preclinical literature indicates that targeting mitochondrial dysfunction may prolong survival in amyotrophic lateral sclerosis, particularly if the intervention is administered early. A limitation of current research is a significant bias towards models based on superoxide dismutase 1, with uncertainty about generalisability to amyotrophic lateral sclerosis with an underlying TAR DNA binding protein 43 proteinopathy. However, further mechanistic research is clearly warranted in this field. Oxford University Press 2019-08-06 /pmc/articles/PMC7056361/ /pubmed/32133457 http://dx.doi.org/10.1093/braincomms/fcz009 Text en © The Author(s) (2019). Published by Oxford University Press on behalf of the Guarantors of Brain. http://creativecommons.org/licenses/by/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Mehta, Arpan R
Walters, Rachel
Waldron, Fergal M
Pal, Suvankar
Selvaraj, Bhuvaneish T
Macleod, Malcolm R
Hardingham, Giles E
Chandran, Siddharthan
Gregory, Jenna M
Targeting mitochondrial dysfunction in amyotrophic lateral sclerosis: a systematic review and meta-analysis
title Targeting mitochondrial dysfunction in amyotrophic lateral sclerosis: a systematic review and meta-analysis
title_full Targeting mitochondrial dysfunction in amyotrophic lateral sclerosis: a systematic review and meta-analysis
title_fullStr Targeting mitochondrial dysfunction in amyotrophic lateral sclerosis: a systematic review and meta-analysis
title_full_unstemmed Targeting mitochondrial dysfunction in amyotrophic lateral sclerosis: a systematic review and meta-analysis
title_short Targeting mitochondrial dysfunction in amyotrophic lateral sclerosis: a systematic review and meta-analysis
title_sort targeting mitochondrial dysfunction in amyotrophic lateral sclerosis: a systematic review and meta-analysis
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7056361/
https://www.ncbi.nlm.nih.gov/pubmed/32133457
http://dx.doi.org/10.1093/braincomms/fcz009
work_keys_str_mv AT mehtaarpanr targetingmitochondrialdysfunctioninamyotrophiclateralsclerosisasystematicreviewandmetaanalysis
AT waltersrachel targetingmitochondrialdysfunctioninamyotrophiclateralsclerosisasystematicreviewandmetaanalysis
AT waldronfergalm targetingmitochondrialdysfunctioninamyotrophiclateralsclerosisasystematicreviewandmetaanalysis
AT palsuvankar targetingmitochondrialdysfunctioninamyotrophiclateralsclerosisasystematicreviewandmetaanalysis
AT selvarajbhuvaneisht targetingmitochondrialdysfunctioninamyotrophiclateralsclerosisasystematicreviewandmetaanalysis
AT macleodmalcolmr targetingmitochondrialdysfunctioninamyotrophiclateralsclerosisasystematicreviewandmetaanalysis
AT hardinghamgilese targetingmitochondrialdysfunctioninamyotrophiclateralsclerosisasystematicreviewandmetaanalysis
AT chandransiddharthan targetingmitochondrialdysfunctioninamyotrophiclateralsclerosisasystematicreviewandmetaanalysis
AT gregoryjennam targetingmitochondrialdysfunctioninamyotrophiclateralsclerosisasystematicreviewandmetaanalysis